Phase I Trials of Molecularly Targeted Agents: Should We Pay More Attention to Late Toxicities?
分子靶向药物I期临床试验:我们更应多注重晚期毒性?
On average, fewer than 5% of participants in phase I trials respond successfully to the treatment.
平均来说,在第一期试验中只有不到5%的参与者对于治疗反应良好。
The real state of the world is that five anti-TB molecules are in phase I trials and two are in phase II.
事实情况是,有五种抗肺结核分子正处于试验阶段I,有两种处于试验阶段II。
应用推荐